Cargando…

Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial( )

AIMS: The presence of pulmonary hypertension (PH) severely aggravates the clinical course of heart failure with preserved ejection fraction (HFpEF). To date, neither established heart failure therapies nor pulmonary vasodilators proved beneficial. This study investigated the efficacy of chronic trea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dachs, Theresa Marie, Duca, Franz, Rettl, René, Binder-Rodriguez, Christina, Dalos, Daniel, Ligios, Luciana Camuz, Kammerlander, Andreas, Grünig, Ekkehard, Pretsch, Ingrid, Steringer-Mascherbauer, Regina, Ablasser, Klemens, Wargenau, Manfred, Mascherbauer, Julia, Lang, Irene M, Hengstenberg, Christian, Badr-Eslam, Roza, Kastner, Johannes, Bonderman, Diana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492239/ https://www.ncbi.nlm.nih.gov/pubmed/35909264 http://dx.doi.org/10.1093/eurheartj/ehac389

Ejemplares similares

Evaluation of the pharmacoDYNAMIC effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction: Study protocol for a randomized controlled trial
por: Mascherbauer, Julia, et al.
Publicado: (2016)

Renin Feedback Is an Independent Predictor of Outcome in HFpEF
por: Binder, Christina, et al.
Publicado: (2021)

Hemodynamic Profiles and Their Prognostic Relevance in Cardiac Amyloidosis
por: Duca, Franz, et al.
Publicado: (2020)

What Type of Patients Did PARAGON-HF Select? Insights from a Real-World Prospective Cohort of Patients with Heart Failure and Preserved Ejection Fraction
por: Rettl, René, et al.
Publicado: (2020)

Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy
por: Rettl, René, et al.
Publicado: (2023)

Serum levels of gamma-glutamyltransferase predict outcome in heart failure with preserved ejection fraction
por: Dalos, Daniel, et al.
Publicado: (2019)

Heart failure with preserved ejection fraction: Calculating the risk of future heart failure events and death
por: Schrutka, Lore, et al.
Publicado: (2022)

Prognostic implications of pericardial and pleural effusion in patients with cardiac amyloidosis
por: Binder, Christina, et al.
Publicado: (2020)

Acute Hemodynamic Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Diastolic Heart Failure (DILATE-1): A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study
por: Bonderman, Diana, et al.
Publicado: (2014)

Persistent atrial fibrillation in heart failure with preserved ejection fraction: Prognostic relevance and association with clinical, imaging and invasive haemodynamic parameters
por: Schönbauer, Robert, et al.
Publicado: (2019)

Machine Learning Enables Prediction of Cardiac Amyloidosis by Routine Laboratory Parameters: A Proof-of-Concept Study
por: Agibetov, Asan, et al.
Publicado: (2020)

Patients with Heart Failure and Preserved Ejection Fraction Are at Risk of Gastrointestinal Bleeding
por: Schrutka, Lore, et al.
Publicado: (2019)

Convolutional Neural Networks for Fully Automated Diagnosis of Cardiac Amyloidosis by Cardiac Magnetic Resonance Imaging
por: Agibetov, Asan, et al.
Publicado: (2021)

Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension
por: Kim, Nick H, et al.
Publicado: (2017)

Presence of ´isolated´ tricuspid regurgitation should prompt the suspicion of heart failure with preserved ejection fraction
por: Mascherbauer, Julia, et al.
Publicado: (2017)

Machine learning-derived electrocardiographic algorithm for the detection of cardiac amyloidosis
por: Schrutka, Lore, et al.
Publicado: (2022)

Functional capacity testing in patients with pulmonary hypertension (PH) using the one-minute sit-to-stand test (1-min STST)
por: Kronberger, Christina, et al.
Publicado: (2023)

Impact of Systemic Volume Status on Cardiac Magnetic Resonance T1 Mapping
por: Antlanger, Marlies, et al.
Publicado: (2018)

Gender-related differences in heart failure with preserved ejection fraction
por: Duca, Franz, et al.
Publicado: (2018)

Gender-specific differences in valvular heart disease
por: Nitsche, Christian, et al.
Publicado: (2020)

Practical management of riociguat in patients with pulmonary arterial hypertension
por: Halank, Michael, et al.
Publicado: (2019)

Prognostic Impact of Tricuspid Regurgitation in Patients Undergoing Aortic Valve Surgery for Aortic Stenosis
por: Mascherbauer, Julia, et al.
Publicado: (2015)

Extracellular volume quantification by cardiac magnetic resonance imaging without hematocrit sampling: Ready for prime time?
por: Kammerlander, Andreas A., et al.
Publicado: (2017)

Prognostic impact of left atrial function in heart failure with preserved ejection fraction in sinus rhythm vs. persistent atrial fibrillation
por: Schönbauer, Robert, et al.
Publicado: (2021)

COVID-19: frequently asked questions to the cardiologist
por: Kammerlander, Andreas A., et al.
Publicado: (2020)

Factors Determining Patient-Prosthesis Mismatch after Aortic Valve Replacement – A Prospective Cohort Study
por: Bonderman, Diana, et al.
Publicado: (2013)

Relevance of Neutrophil Neprilysin in Heart Failure
por: Prausmüller, Suriya, et al.
Publicado: (2021)

Outcome in Heart Failure with Preserved Ejection Fraction: The Role of Myocardial Structure and Right Ventricular Performance
por: Goliasch, Georg, et al.
Publicado: (2015)

Extracellular matrix expansion by cardiac magnetic resonance T1 mapping- validation with myocardial biopsy
por: Kammerlander, Andreas, et al.
Publicado: (2015)

Haemodynamic effects of riociguat in CTEPH and PAH: a 10-year observational study
por: Yang, Suqiao, et al.
Publicado: (2021)

Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH
por: Gall, Henning, et al.
Publicado: (2018)

Cardiac remodeling in ambitious endurance-trained amateur athletes older than 50 years–an observational study
por: Dalos, Daniel, et al.
Publicado: (2022)

Pulmonary artery to aorta ratio for the detection of pulmonary hypertension: cardiovascular magnetic resonance and invasive hemodynamics in heart failure with preserved ejection fraction
por: Karakus, Gültekin, et al.
Publicado: (2015)

Comparison of Hepatic Tissue Characterization between T1-Mapping and Non-Contrast Computed Tomography
por: Bardach, Constanze, et al.
Publicado: (2022)

Right Atrial Phasic Function in Heart Failure with Preserved Ejection Fraction: Cardiac Magnetic Resonance Feature Tracking and Outcomes
por: Schönbauer, Robert, et al.
Publicado: (2023)

Heart failure with preserved ejection fraction after left‐sided valve surgery: prevalent and relevant
por: Kammerlander, Andreas A., et al.
Publicado: (2021)

Editorial: Antithrombotic Treatment in Transcatheter Structural Cardiac Interventions and After Cardiac Device Implantation
por: Siller-Matula, Jolanta M., et al.
Publicado: (2020)

Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies)
por: Ghofrani, Hossein-Ardeschir, et al.
Publicado: (2020)

Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study
por: Simonneau, Gérald, et al.
Publicado: (2020)

Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement
por: Bonderman, Diana, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_og7jjdfka5dseg8ufkdbsveo9f